All In MedTech

FDA Clearance Tracker · P100026-S101

NeuroPace® RNS® System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 28, 2026

Approved

Time to decision

295 days

Received Aug 6, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100026-S101
Device name
NeuroPace® RNS® System
Applicant location
Mountain View, CA
Received
Aug 6, 2025
Decided
May 28, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P100026

Device type

Device class
Class III

Every decision under product code PFN

FDA's approval statement

As written in FDA's record.

approval for an optional Electrocorticogram (ECoG) Assistant function, which is a clinician tool that highlights ECoG recordings of interest, for the Patient Data Management System.

Source documents

Other decisions for NeuroPace, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.